Blue Matter Blog

Five Trends to Watch in the European Market Access Environment
April 2, 2021

Every day, the sun rises and the sun sets. Here’s another thing that’s almost as dependable: national payers in Europe are facing increased pressures on their healthcare budgets. Payers want to provide access and fund innovative treatments to improve patient care, but they need to do so in the context of constrained budgets. However, the …

Success in Rare Diseases, Part V: Working with Payers in the Rare Disease Ecosystem
March 1, 2021

Throughout this series, we’ve covered a wide range of areas that biopharma companies must address if they are to succeed in the rare disease (RD) ecosystem including clinical trial design, clinical trial implementation, and ongoing evidence generation.  In this installment, we cover the important topic of market access. To help drive commercial success, a therapy …

Show Me the Value: Understanding the Payer Landscape and Engaging with Payers in Europe
February 24, 2020

Basic and Essential For any biopharma company planning an initial move into Europe, there are myriad issues to address, as this series outlines.  One of the most important is ensuring that a company’s product(s) will be reimbursed by the various national payers that exist throughout European markets.  It’s a basic truth:  Payers are vital to …

Demonstrating the Value of Rare Disease Treatments
July 25, 2018

Part V in a Series on Rare Diseases At various points in this series, we’ve mentioned that rare disease treatments are usually quite expensive.  In fact, the typical RD treatment costs between $300,000 and $750,000 (US) per year.1 Those high costs reflect two key realities:  1.) Developing new therapies is expensive and risky, and 2.) …